UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey

Journal of antimicrobial chemotherapy, 2020-11, Vol.75 (11), p.3386-3390

2020

Volltextzugriff (PDF)

Recent Approaches to Targeting Canonical NF κ B Signaling in the Early Inflammatory Response to Renal IRI

Journal of the American Society of Nephrology, 2021-09, Vol.32 (9), p.2117-2124

2021

Volltextzugriff (PDF)

Comparison of GPS TEC with modelled values from IRI 2016 and IRI-PLAS over Istanbul, Turkey

Astrophysics and space science, 2018-11, Vol.363 (11), p.1-9, Article 231

Atıcı, Ramazan

2018

Volltextzugriff (PDF)

Obesity Aggravates Ischemia-Reperfusion Injury (IRI)-Induced AKI in Mice: SA-PO072

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.621-621

2022

Volltextzugriff (PDF)

Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study)

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.655-655

2024

Volltextzugriff (PDF)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4190-TPS4190

2023

Volltextzugriff (PDF)

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16116-e16116

2020

Volltextzugriff (PDF)

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.387-387

2023

Volltextzugriff (PDF)

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Annals of oncology, 2020-09, Vol.31, p.S1056-S1056

2020

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS778-TPS778

2023

Volltextzugriff (PDF)

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix74

2017

Volltextzugriff (PDF)

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4196-TPS4196

2022

Volltextzugriff (PDF)

Exposure to Systemic Hypoxia After Renal Ischemia Reperfusion Injury (IRI) Promotes Kidney Repair: SA-PO152

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.766-766

2023

Volltextzugriff (PDF)

Prevention of Ischemia-Reperfusion Injury (IRI)-Induced AKI by Maintaining Na+/K+ ATPase Activity: TH-OR03

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.1-1

2023

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS619-TPS619

2022

Volltextzugriff (PDF)

P31-3 Real-world treatment outcomes of nal-IRI+5FU/LV in unresectable pancreatic cancer

Annals of oncology, 2023-11, Vol.34, p.S1453-S1453

2023

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4170-TPS4170

2021

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS446-TPS446

2021

Volltextzugriff (PDF)

P-26 Is there room for nal-IRI in biliary tract cancer?

Annals of oncology, 2023-06, Vol.34, p.S22-S22

2023

Volltextzugriff (PDF)

MSC-Derived Small Extracellular Vesicles Exert Cardioprotective Effect Through Reducing VLCFAs and Apoptosis in Human Cardiac Organoid IRI Model

Stem cells (Dayton, Ohio), 2024-05, Vol.42 (5), p.416-429

2024

Volltextzugriff (PDF)

Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation

International journal of pharmaceutics, 2020-08, Vol.586, p.119522, Article 119522

2020

Volltextzugriff (PDF)

Assessing dispositional empathy in adults: A French validation of the Interpersonal Reactivity Index (IRI)

Canadian journal of behavioural science, 2013-01, Vol.45 (1), p.42-48

2013

Volltextzugriff (PDF)

Testing the Psychometric Properties of the Interpersonal Reactivity Index (IRI) in Chile: Empathy in a Different Cultural Context

European journal of psychological assessment : official organ of the European Association of Psychological Assessment, 2011, Vol.27 (3), p.179-185

2011

Volltextzugriff (PDF)

1 – 25 von 12.171

Suche als RSS-Feed

Aktive Filter

KollektionSAGE Complete

ThemaInternal Medicine

ThemaMarketing

ThemaMiddle Aged

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11.762)
Mit Volltextzugriff
(10.059)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Full Text
(12.171)
MEDLINE
(5.301)
Ingenta
(4.825)
EZB Electronic Journals Library
(4.543)
SpringerLink
(3.189)
Wiley Online Library Journals
(3.159)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(3.035)
IngentaConnect Journals
(2.467)
Wiley Online Library
(2.455)
NUS Single-Journal Subscriptions
(1.957)
Access via ScienceDirect (Elsevier)
(1.325)
Psychology & Behavioral Sciences Collection
(713)
Oxford Journals
(671)
EZB-NALI5-00465 Elsevier Archive NL
(637)
Access via Business Source (EBSCOhost)
(577)
JSTOR
(525)
Nature Journals Online
(486)
Oxford Journals 2020 Medicine
(465)
Applied Social Sciences Index & Abstracts (ASSIA)
(426)
PsycARTICLES
(343)
Access via SAGE
(0)

16 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Diabetes
(303)
Journal Of Clinical Oncology
(271)
Canadian Journal Of Physiology And Pharmacology
(265)
American Journal Of Transplantation
(249)
Nature
(217)
Canadian Journal Of Chemistry
(142)
The Faseb Journal
(140)
亚太热带医药杂志:英文版
(133)
Transplantation
(123)
Annals Of Oncology
(117)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey

Recent Approaches to Targeting Canonical NF κ B Signaling in the Early Inflammatory Response to Renal IRI

Comparison of GPS TEC with modelled values from IRI 2016 and IRI-PLAS over Istanbul, Turkey

Obesity Aggravates Ischemia-Reperfusion Injury (IRI)-Induced AKI in Mice: SA-PO072

Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Exposure to Systemic Hypoxia After Renal Ischemia Reperfusion Injury (IRI) Promotes Kidney Repair: SA-PO152

Prevention of Ischemia-Reperfusion Injury (IRI)-Induced AKI by Maintaining Na+/K+ ATPase Activity: TH-OR03

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

P31-3 Real-world treatment outcomes of nal-IRI+5FU/LV in unresectable pancreatic cancer

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

P-26 Is there room for nal-IRI in biliary tract cancer?

MSC-Derived Small Extracellular Vesicles Exert Cardioprotective Effect Through Reducing VLCFAs and Apoptosis in Human Cardiac Organoid IRI Model

Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation

Assessing dispositional empathy in adults: A French validation of the Interpersonal Reactivity Index (IRI)

Factors influencing mortality in COVID-19-associated mucormycosis: The international ID-IRI study

Testing the Psychometric Properties of the Interpersonal Reactivity Index (IRI) in Chile: Empathy in a Different Cultural Context

Aktive Filter

Suchergebnisse filtern